CA2659301A1
(en)
*
|
2006-07-28 |
2008-02-07 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
WO2009058911A2
(en)
*
|
2007-10-31 |
2009-05-07 |
Applied Biosystems Inc. |
Preparation and isolation of 5' capped mrna
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
CN101671669B
(zh)
*
|
2009-08-27 |
2012-05-02 |
浙江大学 |
一种肝癌靶向性基因表达元件ae及其应用
|
EP2600901B1
(en)
|
2010-08-06 |
2019-03-27 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
HRP20220796T1
(hr)
|
2010-10-01 |
2022-10-14 |
ModernaTX, Inc. |
Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP3492109B1
(en)
|
2011-10-03 |
2020-03-04 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
RS63244B1
(sr)
|
2011-12-16 |
2022-06-30 |
Modernatx Inc |
Kompozicije modifikovane mrna
|
AU2013225950B2
(en)
|
2012-02-29 |
2018-02-15 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treating huntington's disease
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
US10227610B2
(en)
|
2013-02-25 |
2019-03-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing nuclease-mediated gene disruption
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
CN105934524A
(zh)
|
2013-11-11 |
2016-09-07 |
桑格摩生物科学股份有限公司 |
用于治疗亨廷顿氏病的方法和组合物
|
PL3492593T3
(pl)
|
2013-11-13 |
2022-04-19 |
Children's Medical Center Corporation |
Regulacja ekspresji genów, w której pośredniczą nukleazy
|
EP3757116A1
(en)
|
2013-12-09 |
2020-12-30 |
Sangamo Therapeutics, Inc. |
Methods and compositions for genome engineering
|
EP3090060B1
(en)
|
2013-12-30 |
2019-02-20 |
CureVac AG |
Methods for rna analysis
|
SG10201805660WA
(en)
|
2013-12-30 |
2018-08-30 |
Curevac Ag |
Methods for rna analysis
|
WO2015117081A2
(en)
|
2014-02-03 |
2015-08-06 |
Sangamo Biosciences, Inc. |
Methods and compositions for treatment of a beta thalessemia
|
CA2942762C
(en)
|
2014-03-18 |
2023-10-17 |
Sangamo Biosciences, Inc. |
Methods and compositions for regulation of zinc finger protein expression
|
US9522936B2
(en)
|
2014-04-24 |
2016-12-20 |
Sangamo Biosciences, Inc. |
Engineered transcription activator like effector (TALE) proteins
|
WO2015171932A1
(en)
|
2014-05-08 |
2015-11-12 |
Sangamo Biosciences, Inc. |
Methods and compositions for treating huntington's disease
|
EP3142707A4
(en)
|
2014-05-13 |
2018-02-21 |
Sangamo Therapeutics, Inc. |
Methods and compositions for prevention or treatment of a disease
|
WO2015188065A1
(en)
|
2014-06-05 |
2015-12-10 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease design
|
AU2015273933B2
(en)
|
2014-06-10 |
2021-02-11 |
CureVac Manufacturing GmbH |
Methods and means for enhancing RNA production
|
US9757420B2
(en)
|
2014-07-25 |
2017-09-12 |
Sangamo Therapeutics, Inc. |
Gene editing for HIV gene therapy
|
WO2016019144A2
(en)
|
2014-07-30 |
2016-02-04 |
Sangamo Biosciences, Inc. |
Gene correction of scid-related genes in hematopoietic stem and progenitor cells
|
US10889834B2
(en)
|
2014-12-15 |
2021-01-12 |
Sangamo Therapeutics, Inc. |
Methods and compositions for enhancing targeted transgene integration
|
US20180112213A1
(en)
|
2015-03-25 |
2018-04-26 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
CA2981077A1
(en)
|
2015-04-03 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of genome editing of b-cells
|
EP3603661A3
(en)
|
2015-04-22 |
2020-04-01 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
EP3294896A1
(en)
|
2015-05-11 |
2018-03-21 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
AU2016262521A1
(en)
|
2015-05-11 |
2017-12-14 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating HIV infection and AIDS
|
BR112017024115A2
(pt)
|
2015-05-12 |
2018-08-07 |
Sangamo Therapeutics Inc |
regulação de expressão genética mediada por nuclease
|
PT3303583T
(pt)
|
2015-05-29 |
2020-07-07 |
Curevac Ag |
Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
|
JP7396783B2
(ja)
|
2015-06-09 |
2023-12-12 |
エディタス・メディシン、インコーポレイテッド |
移植を改善するためのcrispr/cas関連方法および組成物
|
US9957501B2
(en)
|
2015-06-18 |
2018-05-01 |
Sangamo Therapeutics, Inc. |
Nuclease-mediated regulation of gene expression
|
WO2017001058A1
(en)
|
2015-07-01 |
2017-01-05 |
Curevac Ag |
Method for analysis of an rna molecule
|
EP3906789B1
(en)
|
2015-09-21 |
2023-11-22 |
TriLink BioTechnologies, LLC |
Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas
|
WO2017053753A1
(en)
|
2015-09-23 |
2017-03-30 |
Sangamo Biosciences, Inc. |
Htt repressors and uses thereof
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
ES2914225T3
(es)
|
2015-10-16 |
2022-06-08 |
Modernatx Inc |
Análogos de cap de ARNm con enlace de fosfato modificado
|
CA3001351A1
(en)
|
2015-10-21 |
2017-04-27 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hepatitis b virus
|
WO2017075475A1
(en)
|
2015-10-30 |
2017-05-04 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus
|
EP3380622A4
(en)
|
2015-11-23 |
2019-08-07 |
Sangamo Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MODIFYING IMMUNITY
|
EP3389677B1
(en)
|
2015-12-18 |
2024-06-26 |
Sangamo Therapeutics, Inc. |
Targeted disruption of the t cell receptor
|
JP2018537112A
(ja)
|
2015-12-18 |
2018-12-20 |
サンガモ セラピューティクス, インコーポレイテッド |
Mhc細胞受容体の標的化破壊
|
WO2017109161A1
(en)
|
2015-12-23 |
2017-06-29 |
Curevac Ag |
Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
PL415967A1
(pl)
*
|
2016-01-29 |
2017-07-31 |
Univ Warszawski |
5'-tiofosforanowe analogi końca 5' mRNA (kapu), sposób ich otrzymywania i zastosowanie
|
US20190049414A1
(en)
|
2016-02-15 |
2019-02-14 |
Curevac Ag |
Method for analyzing by-products of rna in vitro transcription
|
EP3423595A1
(en)
|
2016-03-03 |
2019-01-09 |
CureVac AG |
Rna analysis by total hydrolysis
|
WO2017162265A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Trans-replicating rna
|
WO2017162266A1
(en)
|
2016-03-21 |
2017-09-28 |
Biontech Rna Pharmaceuticals Gmbh |
Rna replicon for versatile and efficient gene expression
|
PL3445850T3
(pl)
|
2016-04-22 |
2022-01-17 |
BioNTech SE |
Sposoby otrzymywania jednoniciowego rna
|
WO2017191264A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Nucleic acid molecules and uses thereof
|
US20180126003A1
(en)
*
|
2016-05-04 |
2018-05-10 |
Curevac Ag |
New targets for rna therapeutics
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
CA3022611A1
(en)
|
2016-05-06 |
2017-11-09 |
Juno Therapeutics, Inc. |
Genetically engineered cells and methods of making the same
|
US11124805B2
(en)
|
2016-07-13 |
2021-09-21 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
WO2018033254A2
(en)
|
2016-08-19 |
2018-02-22 |
Curevac Ag |
Rna for cancer therapy
|
KR20220145913A
(ko)
|
2016-08-24 |
2022-10-31 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
PE20190568A1
(es)
|
2016-08-24 |
2019-04-22 |
Sangamo Therapeutics Inc |
Regulacion de la expresion genica usando nucleasas modificadas
|
US11219695B2
(en)
|
2016-10-20 |
2022-01-11 |
Sangamo Therapeutics, Inc. |
Methods and compositions for the treatment of Fabry disease
|
IL266194B2
(en)
|
2016-10-26 |
2023-09-01 |
Curevac Ag |
mRNA vaccines with lipid nanoparticles
|
US11020492B2
(en)
|
2016-10-31 |
2021-06-01 |
Sangamo Therapeutics, Inc. |
Gene correction of SCID-related genes in hematopoietic stem and progenitor cells
|
CN110214184B
(zh)
|
2016-12-01 |
2024-07-02 |
桑格摩生物治疗股份有限公司 |
τ蛋白调节剂以及用于其递送的方法和组合物
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
CA3054031A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
IL301115A
(en)
|
2017-04-28 |
2023-05-01 |
Acuitas Therapeutics Inc |
New lipid carbonyl and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2018204469A2
(en)
|
2017-05-03 |
2018-11-08 |
Sangamo Therapeutics, Inc. |
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
|
US11512287B2
(en)
|
2017-06-16 |
2022-11-29 |
Sangamo Therapeutics, Inc. |
Targeted disruption of T cell and/or HLA receptors
|
RU2020103379A
(ru)
|
2017-07-04 |
2021-08-04 |
Куревак Аг |
Новые молекулы нуклеиновых кислот
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
WO2019053012A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Rna Pharmaceuticals Gmbh |
RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS
|
MX2020002903A
(es)
|
2017-09-13 |
2020-10-05 |
Biontech Rna Pharmaceuticals Gmbh |
Método para potenciar la expresión de arn en una célula.
|
CA3074919A1
(en)
|
2017-09-13 |
2019-03-21 |
Biontech Cell & Gene Therapies Gmbh |
Rna replicon for expressing a t cell receptor or an artificial t cell receptor
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
KR20200079539A
(ko)
|
2017-11-09 |
2020-07-03 |
상가모 테라퓨틱스, 인코포레이티드 |
시토카인 유도성 sh2-함유 단백질 (cish) 유전자의 유전자 변형
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
US11525158B2
(en)
|
2017-12-21 |
2022-12-13 |
CureVac SE |
Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
|
CA3088791A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency
|
CN111741955B
(zh)
|
2018-01-17 |
2024-02-23 |
沃泰克斯药物股份有限公司 |
Dna-pk抑制剂
|
MA51619A
(fr)
|
2018-01-17 |
2021-04-14 |
Vertex Pharma |
Inhibiteurs de la protéine kinase dépendante de l'adn
|
KR20200143391A
(ko)
*
|
2018-03-15 |
2020-12-23 |
비온테크 알엔에이 파마슈티컬스 게엠베하 |
5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
BR112020020933A2
(pt)
|
2018-04-17 |
2021-04-06 |
Curevac Ag |
Moléculas de rna de rsv inovadoras e composições para vacinação
|
US11690921B2
(en)
|
2018-05-18 |
2023-07-04 |
Sangamo Therapeutics, Inc. |
Delivery of target specific nucleases
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
EP3853244A4
(en)
|
2018-09-18 |
2022-09-14 |
Sangamo Therapeutics, Inc. |
PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES
|
US20220073962A1
(en)
|
2018-12-21 |
2022-03-10 |
Curevac Ag |
Methods for rna analysis
|
EP3897702A2
(en)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Rna for malaria vaccines
|
JP7523449B2
(ja)
|
2019-01-11 |
2024-07-26 |
アクイタス セラピューティクス インコーポレイテッド |
活性剤の脂質ナノ粒子送達のための脂質
|
KR20210116525A
(ko)
|
2019-01-14 |
2021-09-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법
|
EP3920950A1
(en)
|
2019-02-08 |
2021-12-15 |
CureVac AG |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
CN113766921A
(zh)
|
2019-04-23 |
2021-12-07 |
桑格摩生物治疗股份有限公司 |
染色体9开放阅读框72基因表达的调节物及其用途
|
US20220313813A1
(en)
|
2019-06-18 |
2022-10-06 |
Curevac Ag |
Rotavirus mrna vaccine
|
AU2020328855A1
(en)
|
2019-08-14 |
2022-03-03 |
CureVac SE |
RNA combinations and compositions with decreased immunostimulatory properties
|
MX2022007680A
(es)
|
2019-12-20 |
2022-09-26 |
Curevac Ag |
Nanoparticulas lipidicas para administracion de acidos nucleicos.
|
CA3164559A1
(en)
|
2020-01-31 |
2021-08-05 |
Lars Mueller |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
US20240277830A1
(en)
|
2020-02-04 |
2024-08-22 |
CureVac SE |
Coronavirus vaccine
|
DE202021003575U1
(de)
|
2020-02-04 |
2022-01-17 |
Curevac Ag |
Coronavirus-Vakzine
|
CA3174215A1
(en)
|
2020-04-22 |
2021-10-28 |
Ugur Sahin |
Coronavirus vaccine
|
AU2021279312A1
(en)
|
2020-05-29 |
2022-12-15 |
CureVac SE |
Nucleic acid based combination vaccines
|
AU2021286169A1
(en)
|
2020-06-04 |
2023-01-19 |
BioNTech SE |
RNA replicon for versatile and efficient gene expression
|
AU2021308681A1
(en)
|
2020-07-16 |
2023-03-09 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
WO2022023559A1
(en)
|
2020-07-31 |
2022-02-03 |
Curevac Ag |
Nucleic acid encoded antibody mixtures
|
CN113337558A
(zh)
*
|
2020-08-20 |
2021-09-03 |
深圳市瑞吉生物科技有限公司 |
一种Cap2结构5`帽子类似物及其制备方法和应用
|
EP4204545A2
(en)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T cells with improved functionality
|
US20240066114A1
(en)
|
2020-08-31 |
2024-02-29 |
CureVac SE |
Multivalent nucleic acid based coronavirus vaccines
|
AU2021341829A1
(en)
|
2020-09-08 |
2023-04-06 |
BioNTech SE |
Systems and methods for producing pharmaceutical compositions using peristaltic pumps and dampeners
|
CA3201552A1
(en)
|
2020-12-09 |
2022-06-16 |
Thomas ZIEGENHALS |
Rna manufacturing
|
WO2022135993A2
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
KR20230164648A
(ko)
|
2020-12-22 |
2023-12-04 |
큐어백 에스이 |
SARS-CoV-2 변이체에 대한 RNA 백신
|
US20240102065A1
(en)
|
2021-01-27 |
2024-03-28 |
CureVac SE |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
EP4313152A1
(en)
|
2021-03-26 |
2024-02-07 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic compositions
|
WO2022207862A2
(en)
|
2021-03-31 |
2022-10-06 |
Curevac Ag |
Syringes containing pharmaceutical compositions comprising rna
|
EP4334446A1
(en)
|
2021-05-03 |
2024-03-13 |
CureVac SE |
Improved nucleic acid sequence for cell type specific expression
|
AU2022270658A1
(en)
|
2021-05-04 |
2023-11-16 |
BioNTech SE |
Technologies for early detection of variants of interest
|
BR112024001180A2
(pt)
|
2021-07-29 |
2024-04-30 |
BioNTech SE |
Composições e métodos para tratamento do melanoma
|
WO2023006999A2
(en)
|
2021-07-30 |
2023-02-02 |
CureVac SE |
Mrnas for treatment or prophylaxis of liver diseases
|
CN117940158A
(zh)
|
2021-09-03 |
2024-04-26 |
库瑞瓦格欧洲公司 |
用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
|
EP4395748A1
(en)
|
2021-09-03 |
2024-07-10 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids
|
CN113957108A
(zh)
*
|
2021-09-09 |
2022-01-21 |
上海兆维科技发展有限公司 |
一种加帽rna的合成方法以及加帽rna转录反应液
|
CA3234396A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Modified replicable rna and related compositions and their use
|
WO2023066874A1
(en)
|
2021-10-18 |
2023-04-27 |
BioNTech SE |
Methods for determining mutations for increasing modified replicable rna function and related compositions and their use
|
WO2023138786A1
(en)
|
2022-01-21 |
2023-07-27 |
BioNTech SE |
Analysis of rna molecules using catalytic nucleic acids
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023166425A1
(en)
|
2022-03-01 |
2023-09-07 |
Crispr Therapeutics Ag |
Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
|
WO2023180904A1
(en)
|
2022-03-21 |
2023-09-28 |
Crispr Therapeutics Ag |
Methods and compositions for treating lipoprotein-related diseases
|
WO2023213378A1
(en)
|
2022-05-02 |
2023-11-09 |
BioNTech SE |
Replicon compositions and methods of using same for the treatment of diseases
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023237726A1
(en)
|
2022-06-10 |
2023-12-14 |
Pantarhei Oncology B.V. |
An intracellular tumor-specific variant of human zona pellucida glycoprotein 3 and nucleic acids coding therefor for use in the treatment of cancer
|
US11878055B1
(en)
|
2022-06-26 |
2024-01-23 |
BioNTech SE |
Coronavirus vaccine
|
CN114941018B
(zh)
*
|
2022-06-28 |
2023-09-22 |
翌圣生物科技(上海)股份有限公司 |
cap1帽类似物的合成方法
|
WO2024017479A1
(en)
|
2022-07-21 |
2024-01-25 |
BioNTech SE |
Multifunctional cells transiently expressing an immune receptor and one or more cytokines, their use and methods for their production
|
WO2024056856A1
(en)
|
2022-09-15 |
2024-03-21 |
BioNTech SE |
Systems and compositions comprising trans-amplifying rna vectors with mirna
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
US20240156949A1
(en)
|
2022-10-28 |
2024-05-16 |
Glaxosmithkline Biologicals Sa |
Nucleic Acid Based Vaccine
|
WO2024137589A2
(en)
|
2022-12-20 |
2024-06-27 |
Genentech, Inc. |
Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
|
WO2024160936A1
(en)
|
2023-02-03 |
2024-08-08 |
Glaxosmithkline Biologicals Sa |
Rna formulation
|
WO2024165146A1
(en)
|
2023-02-07 |
2024-08-15 |
Biontech Cell & Gene Therapies Gmbh |
Immune effector cells stably and transiently expressing nucleic acids
|
GB202302092D0
(en)
|
2023-02-14 |
2023-03-29 |
Glaxosmithkline Biologicals Sa |
Analytical method
|
WO2024184500A1
(en)
|
2023-03-08 |
2024-09-12 |
CureVac SE |
Novel lipid nanoparticle formulations for delivery of nucleic acids
|
WO2024193827A1
(en)
|
2023-03-23 |
2024-09-26 |
BioNTech SE |
Stabilized nucleic acid compositions and methods for preparing, storing and using the same
|
GB202404607D0
(en)
|
2024-03-29 |
2024-05-15 |
Glaxosmithkline Biologicals Sa |
RNA formulation
|